Clinical trials: Albuminuria
Diabetes Mellitus, Type 2, Albuminuria
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and…
- Trial name
- CANVAS-R (NCT01989754)
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 341 sites in United States, Argentina and 23 more
- Volunteers
- 5,813 people
- Sponsor
- Janssen Research & Development, LLC
Hypertension, Diabetes Mellitus, Type 2
ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria
The purpose of the study is to compare the change from baseline in blood pressures (DBP/SBP) to 16-week regimen between Amtrel® and Co-Diovan®. The secondary objectives were listed as the following.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Albuminuria
- Trial name
- NCT01375322
- Testing
- Amlodipine+Benazepril, Valsartan+Hydrochlorothiazide
- Where
- 4 sites in Taiwan
- Volunteers
- 226 people
- Sponsor
- TSH Biopharm Corporation Limited
Hypertension, Diabetes
A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.
- Trial name
- BENEDICT (NCT00235014)
- Testing
- trandolapril, trandolapril/verapamil, verapamil
- Volunteers
- 1,204 people
- Sponsor
- Abbott
Chronic Kidney Disease, Diabetic Nephropathy
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared…
- Trial name
- RADAR (NCT01356849)
- Testing
- Atrasentan
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease and Hypertension
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with…
- Trial name
- BaxDuo-Baltic (NCT07222917)
- Testing
- Baxdrostat/dapagliflozin
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Hypertension, Early Diabetic Nephropathy
Antialbuminuric Effects of Valsartan and Lisinopril
Title: Antialbuminuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), open label, parallel group, 20 weeks follow-up.
- Trial name
- NCT00171600
- Testing
- VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus, Hypertension
Shiga Microalbuminuria Reduction Trial-2
The purpose of this study is to compare the effects of a direct renin inhibitor (DRI), aliskiren, on the urinary albumin excretion in hypertensive patients with type 2 diabetes under strict blood pressure control with angiotensin…
- Trial name
- NCT01461499
- Testing
- Aliskiren, any angiotensin receptor blockers
- Where
- Japan
- Volunteers
- 237 people
- Sponsor
- Shiga University
Hypertension, Type 2 Diabetes
Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes
The purpose of this study is to determine if a dose of ramipril combined with a normal dose of telmisartan 80 mg will be more effective than ramipril 20 mg in reducing microalbuminuria in hypertensive patients with diabetes.
- Conditions
- Hypertension, Type 2 Diabetes, Albuminuria
- Trial name
- NCT00208221
- Testing
- ramipril, ramipril-telmisartan
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Chronic Kidney Disease stage3
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of orally drugs for the treatment of type 2 diabetes. These drugs decrease plasma glucose levels by inhibiting its reabsorption in the proximal tubules of the…
- Trial name
- NCT04961931
- Testing
- Empagliflozin 10 MG
- Where
- Poland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Cardiovascular Disease, Type 2 Diabetes Mellitus
PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study
The association between Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) is well established. Traditional risk factors for CVD and CKD are similar, with type 2 diabetes mellitus (T2DM) being the most prevalent risk…
- Trial name
- PLACARD (NCT06336239)
- Where
- 27 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Anzhen Hospital
Diabetic Nephropathy
Aldosterone in Diabetic Nephropathy
The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.
- Trial name
- ALDODN (NCT00870402)
- Testing
- Spironolactone
- Where
- Chile
- Volunteers
- 160 people
- Sponsor
- Universidad de los Andes, Chile
Diabetes, Hypertensive Disease
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
Diabetes is the leading cause of chronic kidney disease in developed countries. About 30-40% of patients with type 1 and type 2 diabetes mellitus will develop diabetic nephropathy.
- Trial name
- eGFR (NCT01500590)
- Testing
- Renin-angiotensin system blockers, non-renin angiotensin system blockers
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Hospital Authority, Hong Kong
Diabetes Mellitus, Endothelial Dysfunction
Aldosterone and Vascular Disease in Diabetes Mellitus
Specific aims for this proposal are to determine in patients with diabetes mellitus the effects of an aldosterone receptor antagonist on: 1. Coronary microvascular function assessed by MRI perfusion reserve, 2.
- Conditions
- Diabetes Mellitus, Endothelial Dysfunction, Albuminuria
- Trial name
- NCT00214825
- Testing
- eplerenone, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Brigham and Women's Hospital
Chronic Kidney Disease
Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide
The FINESSE-CKD trial investigates a personalized approach to the treatment of chronic kidney disease (CKD) by comparing the effects of finerenone and semaglutide on albuminuria.
- Trial name
- FINESSE-CKD (NCT07819227)
- Testing
- Finerenone (BAY 94-8862), Semaglutide 14 MG [Rybelsus], Finerenone and Semaglutide
- Where
- 6 sites in Denmark, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- University Medical Center Groningen
Alport Syndrome, Thin Basement Membrane Disease
Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)
Alport syndrome (AS) is one of the most common monogenic kidney disorders, oftentimes leading to end-stage kidney disease (ESKD).
- Conditions
- Alport Syndrome, Thin Basement Membrane Disease, Alport Nephropathy
- Trial name
- COMBINE-ALPORT (NCT06499948)
- Testing
- Treatment with Spironolactone followed by Dapagliflozin followed by their combination, Treatment with Dapagliflozin followed by Spironolactone followed by their combination
- Where
- Romania
- Volunteers
- 12 people
- Sponsor
- Stefan Lujinschi
Sickle Cell Disease
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
The purpose of this phase IIb, international, multicentre, double-blind, randomised, placebo-controlled study is to determine the effect of hydroxycarbamide on albuminuria after 6 months of treatment in SCD adult patients.
- Trial name
- SIKAMIC (NCT03806452)
- Testing
- Hydroxycarbamide
- Where
- 21 sites in Côte d’Ivoire, France and 4 more
- Volunteers
- 86 people
- Sponsor
- Theravia
Albuminuria
Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands
Eligible subjects meeting the pathological profile will be recruited at the designated site by the study personnel. Following subject consent, the subjects will be evaluated for eligibility based on their health condition and…
- Trial name
- NCT04626271
- Testing
- ACR | U.S. Urine Analysis Test System, URiSCAN Optima Urine Analyzer
- Where
- 2 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Healthy.io Ltd.
Chronic Kidney Diseases, Type 2 Diabetes Mellitus
Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa
Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA).
- Conditions
- Chronic Kidney Diseases, Type 2 Diabetes Mellitus, Arterial Hypertension, Obesity
- Trial name
- RenalTWO (NCT05881447)
- Where
- Tanzania
- Volunteers
- 1,200 people
- Sponsor
- Swiss Tropical & Public Health Institute
Chronic Kidney Disease, Type 2 Diabetes
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.
- Trial name
- RAPID-CKD (NCT07547878)
- Testing
- Finerenone, Semaglutide, Lotensin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Baylor Research Institute
Renal Transplant Failure, Cardiovascular Complication
Cardiorenal Effecs of Losartan in Kidney Transplant Recipients
The influence of Losartan to cardiovascular and renal outcomes in patients after renal transplatation.
- Trial name
- CELART (NCT05243446)
- Testing
- Losartan
- Where
- Poland
- Volunteers
- 740 people
- Sponsor
- Medical University of Gdansk